Novartis receives US FDA accelerated approval for Fabhalta, the first and only complement inhibitor for reduction of ...
Novartis announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) …